LANCET ONCOLOGY, cilt.21, sa.1, ss.105-120, 2020 (SCI-Expanded)
Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial.